Vaccine News and Research

Latest Vaccine News and Research

Does vaccination prevent long COVID?

In a recent study, researchers evaluate the effect of COVID-19 vaccination on a large ongoing prospective cohort of patients with long COVID.

6 Oct 2021

Moderna COVID vaccine booster dose results in immune memory

A recent study presents evidence that a booster dose of the Moderna vaccine can induce a robust memory immune response against COVID-19.

6 Oct 2021

Research on twins indicates strong genetic influences in COVID-19

A new study discusses the strong possibility of multifactorial causation for SARS-CoV-2 infection using data from twin studies.

6 Oct 2021

KU Leuven researchers develop an ultrapotent inhibitor of dengue virus

Researchers at the KU Leuven Rega Institute and CD3 have developed an ultrapotent inhibitor of the dengue virus, which causes the tropical disease known as dengue.

6 Oct 2021

Characteristics of unvaccinated individuals from the University of Southern California

A recent study examines the characteristics of university staff and faculty who remained unvaccinated against COVID-19.

6 Oct 2021

Study finds increased risk for SARS-CoV-2 breakthrough infections in people with substance use disorders

An analysis of electronic health records of nearly 580,000 fully vaccinated people in the United States found that the risk of SARS-CoV-2 breakthrough infection among vaccinated patients with substance use disorders was low overall, but higher than the risk among vaccinated people without substance use disorders.

6 Oct 2021

California vaccine mandate extends to aides for people with disabilities

Workers in adult and senior care facilities and in-home aides have been added to the list of California health workers who must be fully vaccinated against the coronavirus.

6 Oct 2021

Comparative analysis between the SARS-CoV-1 and SARS-CoV-2 mPro systems

To better understand the biophysical changes that occur due to mutations, the mechanisms of multiple SARS-CoV-2 proteins have been studied and compared with SARS-CoV-1.

6 Oct 2021

Acute myocarditis extremely rare after COVID mRNA vaccination in adults

Now, a new study published in the journal JAMA Internal Medicine evaluated the incidence of acute myocarditis and clinical outcomes among adults who received the mRNA vaccine in an integrated health care system in the United States.

5 Oct 2021

Research highlights challenges in utilizing Ct data to guide COVID-19 clinical planning

In a new study, a collaboration of researchers from various institutes described the natural history of SARS-CoV-2 testing, which includes Ct values among patients who had tested positive multiple times, prior to the emergence of VOCs in the vaccine roll-out. In addition, the authors analyze the timescale of positivity and clinical features of the population of patients with prolonged SARS-CoV-2 positivity.

5 Oct 2021

SARS-CoV-2 variants of concern more virulent than the native strain of the virus

A large study from Ontario confirms that SARS-CoV-2 variants of concern (VOCs), especially the Delta variant, are more virulent than the native strain of the virus, increasing people's risk of hospitalization, admission to the intensive care unit (ICU) and death due to COVID-19.

5 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.

5 Oct 2021

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

A new study shows that up to a third of survivors in LTCFs were infected during the first year after infection.

5 Oct 2021

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

One recent study assessed the serum of Beta variant infected patients to determine whether major non-VOC antibodies could neutralize this virus.

5 Oct 2021

Anti-CD20 therapy patients can develop immune responses after SARS-CoV-2 vaccination

A new systematic review and meta-analysis focused on the humoral and cell-mediated immune responses after COVID-19 vaccination in patients undergoing anti-CD20 antibodies treatment.

5 Oct 2021

Depressed seroconversion in immunocompromised COVID-19 vaccine recipients

Researchers from the University of Singapore have reviewed the data in post-vaccinated immunocompromised patients to examine the effectiveness of these vaccines in these patients.

5 Oct 2021

How accurate is COVID-19 modeling?

Researchers from the Burnet Institute in Melbourne have been using this to investigate how accurate COVID-19 modelling has been.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021